26 filings
6-K
AKTX
Akari Therapeutics Plc
23 Dec 19
Current report (foreign)
9:08am
6-K
AKTX
Akari Therapeutics Plc
2 Dec 19
Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence
4:44pm
6-K
AKTX
Akari Therapeutics Plc
27 Nov 19
Current report (foreign)
4:31pm
6-K
AKTX
Akari Therapeutics Plc
27 Nov 19
Akari Therapeutics Reports Revised Third Quarter 2019 Financial Results
4:30pm
6-K
AKTX
Akari Therapeutics Plc
15 Oct 19
Current report (foreign)
7:06am
6-K
nqi40
10 Oct 19
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress
9:02am
6-K
con2dv
13 Sep 19
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid
8:16am
6-K
4c4xwb659602ya
10 Sep 19
September 2019 Investor Presentation Copyright Akari Therapeutics, Plc - 2019
8:20am
6-K
wdhw4q4ch
30 Aug 19
Current report (foreign)
8:12am
6-K
fba6x8edxodjxdn
29 Aug 19
Current report (foreign)
8:28am
6-K
ycd0mnhr
14 Aug 19
Current report (foreign)
12:00am
6-K
ql59mg
9 Aug 19
Current report (foreign)
8:52am
6-K
2fq1asy4ic
2 Jul 19
Current report (foreign)
4:20pm
6-K
szkjmrm6x35mu9w
28 Jun 19
Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering
4:35pm
6-K
fqe ysqfrd
27 Jun 19
Current report (foreign)
4:32pm
6-K
hl5yo0khunwl6j52smc
25 Jun 19
Current report (foreign)
4:31pm
6-K
5zhrio qyrrbr2cck
19 Jun 19
Current report (foreign)
4:30pm
6-K
5ktdsm86
6 Jun 19
Consolidated Annual Report and Financial Statements
5:15pm
6-K
ievekmcswmys9t
29 May 19
Current report (foreign)
4:15pm
6-K
8uifv876xwh nb4dl0x3
29 May 19
This Document Is Important and Requires Your Immediate Attention
7:00am